secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001193125-25-178954
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q2 net income $0.2M; YCANTH units +32.8% QoQ; Nasdaq compliance regained
--------------------------------------------------------------------------------

- Q2 product revenue $4.5M; license & collaboration revenue $8.2M (incl. $8.0M Torii milestone). Net income $0.2M ($0.02 GAAP EPS) vs net loss $17.2M YoY.
- YCANTH dispensed applicator units 13,434, sequential growth of 32.8% over Q1'25. Revenue net $4.5M up 32.5% sequentially.
- Regained Nasdaq bid price compliance after 1-for-10 reverse stock split on July 24, 2025.
- Torii accelerated $8M milestone payment received July 2025; additional $10M milestone upon Japanese YCANTH approval expected by end of 2025.
- Completed End-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); preparing Phase 3 program and exploring non-dilutive funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/0001193125-25-178954-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/d409147d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-178954

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer